Author Archives: Özge Özkaya, PhD

Fat-free mass index (FFMI), a measure similar to body mass index (BMI) but that also takes into account the amount of muscle mass in the body is a significant predictor of survival in idiopathic pulmonary fibrosis (IPF) patients.

Treating idiopathic pulmonary fibrosis (IPF) patients with the anti-IPF drug Esbriet (pirfenidone) before and after lung surgery could be protective against acute exacerbation, or worsening of IPF, a life-threatening complication associated with lung-cancer surgery.

The effectiveness of long-term treatment with the anti fibrotic drug Esbriet (pirfenidone) for more than 3 years does not depend on the forced vital capacity (FVC) at baseline in patients with idiopathic pulmonary fibrosis (IPF), according to a clinical trial called RECAP (NCT00662038).

Treatment with Ofev (nintedanib) is associated with stabilization of lung function in patients with idiopathic pulmonary fibrosis (IPF) according to a study published in the scientific journal Respiration.

Researchers are one step closer to understanding the molecular mechanism of action of pirfenidone, the anti fibrotic drug for the treatment of pulmonary fibrosis. This may help improve the safety and efficacy of the drug, which is often used in very high doses to achieve therapeutic effectiveness, causing a range of adverse side effects.

Metformin, a first line medication for the treatment of type 2 diabetes, reduces inflammation and pulmonary fibrosis in mice, suggests a study published in the Journal of Korean Medical Science.

The U.S. Department of Defense granted $11.5 million to researchers at National Jewish Health, one of the leading respiratory hospitals in the country, for two research projects investigating lung disease including pulmonary fibrosis in warfighters deployed to Southwest Asia.

A new review covering the benefits of exercise training in idiopathic pulmonary fibrosis (IPF) has been recently published in the journal Breathe.

Pulmatrix, a clinical stage biopharmaceutical company, recently released an animated life sciences video describing their new dry powder inhaler system called Isperse for lung disease patients.

OFEV (nintedanib) is effective for a wide range of idiopathic pulmonary fibrosis (IPF) patients according to Boehringer Ingelheim, the company that developed the drug.